PMID- 34737945
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220428
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced 
      Hepatocellular Carcinoma: A Retrospective Analysis.
PG  - 694409
LID - 10.3389/fonc.2021.694409 [doi]
LID - 694409
AB  - BACKGROUND: Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with 
      poor prognosis. Immunotherapy has gained great interest for various solid tumors 
      due to its promising clinical efficacy. Targeted therapy also plays a crucial 
      role in anticancer treatment. However, studies on the combination of 
      immunotherapy and targeted therapy for advanced HCC are limited. Thus, the 
      objective of this study was to investigate the efficacy and safety of 
      camrelizumab combined with sorafenib in the treatment of advanced HCC. METHODS: 
      From January 2019 to January 2021, 100 consecutive patients with advanced HCC in 
      our hospital were enrolled for this study. Patients were assigned into two 
      groups: a combined-therapy group (camrelizumab + sorafenib) and a sorafenib-only 
      group. Progression-free survival (PFS), overall survival (OS), treatment 
      response, and relevant adverse effects (AEs) were evaluated and recorded. 
      RESULTS: Of a total of 100 patients, 35 received a combination of camrelizumab 
      and sorafenib, and 65 were treated with sorafenib alone. After 1:1 propensity 
      score matching (PSM), each group had 34 patients. The overall response rate (ORR) 
      of the combined-therapy group was statistically significantly higher than that of 
      the sorafenib-only group (before PSM, p = 0.037; after PSM, p = 0.010). However, 
      there was no significant difference in disease control rate (DCR) between the two 
      groups (before PSM, p = 0.695; after PSM, p = 1.000). Patients who received the 
      combination therapy had significantly longer PFS than those who received the 
      sorafenib monotherapy (before PSM, p = 0.041; after PSM, p = 0.043). However, the 
      two groups exhibited comparable median OS (before PSM, p = 0.135; after PSM, p = 
      0.105). Although the combined-therapy group showed a higher incidence of AEs such 
      as thrombocytopenia than the sorafenib-only group after PSM, most of these AEs 
      were easily controlled after treatment. CONCLUSION: Camrelizumab plus sorafenib 
      showed favorable efficacy and manageable toxicity for patients with advanced HCC. 
      However, more prospective randomized trials are necessary to further verify the 
      potential clinical benefits of this combination therapy.
CI  - Copyright (c) 2021 Liu, You, Li, Wu, Peng, Wang, Wang, Zhu and Zheng.
FAU - Liu, Qinqin
AU  - Liu Q
AD  - Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army 
      Medical University, Chongqing, China.
AD  - Department of Biliary-Pancreatic Surgery, Sun Yat-Sen Memorial Hospital, Sun 
      Yat-Sen University, Guangzhou, China.
FAU - You, Nan
AU  - You N
AD  - Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army 
      Medical University, Chongqing, China.
FAU - Li, Jing
AU  - Li J
AD  - Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army 
      Medical University, Chongqing, China.
FAU - Wu, Ke
AU  - Wu K
AD  - Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army 
      Medical University, Chongqing, China.
FAU - Peng, Xuehui
AU  - Peng X
AD  - Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army 
      Medical University, Chongqing, China.
FAU - Wang, Zheng
AU  - Wang Z
AD  - Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army 
      Medical University, Chongqing, China.
FAU - Wang, Liang
AU  - Wang L
AD  - Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army 
      Medical University, Chongqing, China.
FAU - Zhu, Yinan
AU  - Zhu Y
AD  - Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army 
      Medical University, Chongqing, China.
FAU - Zheng, Lu
AU  - Zheng L
AD  - Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Army 
      Medical University, Chongqing, China.
LA  - eng
PT  - Journal Article
DEP - 20211019
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8560727
OTO - NOTNLM
OT  - camrelizumab
OT  - efficacy
OT  - hepatocellular carcinoma
OT  - safety
OT  - sorafenib
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/11/06 06:00
MHDA- 2021/11/06 06:01
PMCR- 2021/01/01
CRDT- 2021/11/05 06:50
PHST- 2021/04/13 00:00 [received]
PHST- 2021/09/06 00:00 [accepted]
PHST- 2021/11/05 06:50 [entrez]
PHST- 2021/11/06 06:00 [pubmed]
PHST- 2021/11/06 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.694409 [doi]
PST - epublish
SO  - Front Oncol. 2021 Oct 19;11:694409. doi: 10.3389/fonc.2021.694409. eCollection 
      2021.